Propranolol restricts the mobility of single EGF-receptors on the cell surface before their internalization

Carolina Otero1, Max Linke2, Paula Sanchez3

  • 1Center for Integrative Medicine and Innovative Science (CIMIS), Universidad Andres Bello, Santiago, Chile ; Centro para el Desarrollo de la Nanociencia y Nanotecnologia, Santiago, Chile.

Plos One
|December 19, 2013
PubMed

Insights

Propranolol treatment alters epidermal growth factor receptor (EGFR) mobility, reducing diffusion and increasing stalling. This suggests EGFR clustering is key to its reduced mobility and may initiate receptor internalization.

Area of Science:

  • Cell biology
  • Molecular biology
  • Biophysics

Background:

  • Epidermal growth factor receptor (EGFR) is crucial for cell functions and a therapeutic target in cancer.
  • EGFR up-regulation is linked to tumorigenesis.
  • The mechanism of EGFR internalization, particularly of inactive receptors, is not fully understood.

Purpose of the Study:

  • To investigate the effects of propranolol on single epidermal growth factor receptor (EGFR) mobility.
  • To elucidate the molecular events preceding EGFR internalization.

Main Methods:

  • Utilized quantum dot-labeling to track single EGFR mobility.
  • Quantified receptor diffusion and stalling dynamics.
  • Employed atomic force microscopy to assess membrane tension.

Main Results:

  • Propranolol reduced EGFR diffusion rate by 22%, indicating increased drag, likely due to receptor clustering.
  • Atomic force microscopy ruled out increased membrane tension as the cause of reduced mobility.
  • Receptors exhibited prolonged stalling events (multiple seconds) in the presence of propranolol.

Conclusions:

  • Propranolol induces EGFR clustering, leading to reduced receptor mobility.
  • Prolonged receptor stalling may represent an early step in the internalization process of inactive EGFR.

Related Concept Videos

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
1.8K
Antihypertensive Drugs: Types of β-Blockers01:28

Antihypertensive Drugs: Types of β-Blockers

β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and...
2.0K
GPCR Desensitization01:12

GPCR Desensitization

G protein-coupled receptor (GPCR) signaling plays a crucial role in cell functioning. GPCR desensitization is an equally essential process. It allows cells to respond to changing environments and regain sensitivity to new stimuli while preventing unnecessary stimulation when no longer needed. Prolonged exposure to stimuli leads to GPCR desensitization. It involves blocking the receptors from binding and activating additional G proteins. This inhibits activation of downstream effectors, thereby...
6.1K
GPCRs Regulate Adenylyl Cylase Activity01:09

GPCRs Regulate Adenylyl Cylase Activity

Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of...
6.9K
Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers01:25

Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers

β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but...
1.7K
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
1.4K